Current biomarker assessment tools for neurodevelopmental diseases like PMS can be imprecise and subject to bias, making it harder to objectively measure a treatment's impact. CureSHANK is actively working with expects to evaluate promising biomarker approaches that will provide more accurate and objective measurements for PMS research.

CureSHANK’s 3rd annual Phelan-McDermid Syndrome Drug Development Symposium brought together researchers, clinicians, industry leaders, and families for two days of remarkable science, community, and hope. Read on for key takeaways and insights that will shape the future of PMS drug development.